On September 15, 2020 Van Andel Institute’s Biorepository reported that has been awarded a $2.7 million, two-year subcontract from the Frederick National Laboratory for Cancer Research currently operated by Leidos Biomedical Research, Inc. on behalf of the National Cancer Institute to serve as the biorepository for the Cancer Moonshot Biobank study, a national initiative to transform cancer treatment and prevention through accelerated research (Press release, Van Andel Institute, SEP 15, 2020, View Source;utm_medium=rss&utm_campaign=cancer-moonshot-biorepository-announcement [SID1234565167]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In this role, VAI will assemble and distribute kits for the collection of tumor tissue, blood and other biospecimens to hospitals and medical centers around the U.S. Once samples are collected from volunteers, they will be shipped to VAI for processing and either stored for later study or sent to other organizations conducting analyses for the Cancer Moonshot. In all, the Biobank project is expected to collect biospecimens from more than 1,000 participants.
"Biospecimens are the bedrock of scientific research — without them, we wouldn’t be able to study cancer or develop new treatments and diagnostics," said Scott Jewell, Ph.D., director of VAI’s Core Technologies and Services, which includes the Institute’s Biorepository. "We are honored to be part of the Cancer Moonshot Biobank study and look forward to doing our part to support research and improve cancer care."
The Cancer Moonshot was launched in 2016 by the Obama Administration. Its strategic aims, determined by a Blue Ribbon Panel of experts, are designed to answer critical scientific and medical questions while ensuring the samples collected represent the diversity of the U.S. population.
VAI’s Biorepository provides services for a number of large-scale national and international projects, including NIH’s Clinical Proteomic Tumor Analysis Consortium and the National Cancer Institute’s Biospecimen Pre-Analytical Variables Program. The Biorepository team also played an integral role in biospecimen collection for the NIH’s Genotype-Tissue Expression project, including developing and shipping the kits used by investigators around the country to collect tissue samples. It currently serves as the biobank for the Multiple Myeloma Research Foundation’s CoMMpass Study, the Tuberous Sclerosis Alliance and the Van Andel Institute–Stand Up To Cancer Epigenetics Dream Team. Since 2012, VAI’s Biorepository has been accredited by the College of American Pathologists (no. 8017856), which provides objective assurance that VAI meets or exceeds the high standards set by CAP.
The project has been funded in whole or in part with federal funds from the National Cancer Institute of the National Institutes of Health under contract no. HHSN261201500003I, Task Order HHSN26100042 through Leidos Biomedical Research, Inc. under subcontract no. 20X062Q. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the U.S. government.